Author:
Portell Craig A.,Advani Anjali S.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Reference34 articles.
1. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760–7.
2. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944–50.
3. Paietta E, Li X, Richards S, et al. Implications for the use of monoclonal antibodies in future adult ALL trials: analysis of antigen expression in 505 B-Lineage (B-Lin) all patients (pts) on the MRC UKALLXII/ECOG2993 intergroup trial [abstract]. Proc ASH. 2008;112:1907. http://bloodjournal.hematologylibrary.org .
4. • Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52:1098–107. Lists clinical characteristics of CD19, CD20, CD22, and CD33 expression in ALL.
5. • Thomas DA, O’Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009;113:6330–7. CD20 expression denotes a poor prognosis in precursor B-ALL.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献